As an experienced urologist and member of GU CONNECT, Prof. David Pfister provides his perspective on new therapies for mHSPC.

After finishing medical school in November 2004 Dr Pfister started his residency in the Department of Urology at the University of Cologne. For his endoscopic training, he switched to the General Hospital in Weiden (Oberpfalz/Bavaria) between August 2006 and March 2007. After returning to Cologne Dr Pfister heightened my oncologic education under Prof. Heidenreich. The oncologic training consisted of two arms: medical and surgical oncology. In 2009 his education was augmented at the University Hospital of Aachen. In 2010 he passed his urologic board exam. Since 2011 Dr Pfister has been working as a staff urologist with main interests in castration-resistant prostate cancer and testicular cancer. In 2011 he passed the Charles Huggins grant, an educational grant at the Center for Prostate Disease Research in Maryland, USA. In 2012 Dr Pfister received an additional qualification in the systemic treatment of solid tumours and since that time he has organised and led the urological clinical trial centre. In 2012 Dr Pfister qualified as a Professor and became an Associate Professor in November 2012 for medical oncologic treatment in urological tumours. At the end of 2015 he became the Commissionary Leader of the Urologic Department of the University of Aachen. Since 2016 Dr Pfister has become the Deputy Director of the Department of Urology, Uro-oncology and Robot-Assisted Surgery, University Hospital of Cologne. Special interest is castration-resistant, radiation-resistant prostate cancer and testicular cancer.

Prof. David Pfister has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

AstraZeneca, Bayer, Merck, MSD, Janssen and Pfizer. 

Programme summary
Watch the video now
Share this programme
This educational programme is supported by an Independent Educational Grant from Bayer
I agree that this educational programme:

Was valuable to me

1/4
Brought to you by
GU CONNECT

GU CONNECT is an initiative of COR2ED, supported by Independent Educational Grants from AstraZeneca, Bayer and Eisai Europe Limited.

Meet the experts Independent IME approved

Other programmes of interest

video Video
Oncology 
Recent advances in precision oncology and future implications

Two emerging and two established targets

Experts
Prof. David Hong
  • download Downloadable
    Resources
  • clock 4 MIN
  • calendar Dec 2024

Educational programme supported by an Independent Educational Grant from Bayer.
publication Publication
Oncology 
Survey on the evolving role of the oncology nurse in the USA

Announcing the publication of survey results 

Experts
Nina Grenon, Natasha Pinheiro, Karen Waldrop, Brittni Prosdocimo
  • download Downloadable
    Resources
  • clock 10 MIN
  • calendar Dec 2024

Educational programme supported by an Independent Educational Grant from Bayer.
video Video
Oncology 
Elacestrant in ER+/HER2- metastatic breast cancer

An expert overview of the EMERALD subgroup analysis

Experts
Dr Virginia Kaklamani
  • download Downloadable
    Resources
  • clock 4 MIN
  • calendar Dec 2024

This programme has been sponsored by Menarini Stemline and is intended for healthcare professionals only.
video Video
Oncology 
Systemic treatment options for patients with non-clear cell renal cell carcinoma (nccRCC)

Managing patients with nccRCC: guidelines, recommendations, and best practice

Experts
Prof. Laurence Albiges
Endorsed by
Urobel VZW | ASBL
  • download Downloadable
    Resources
  • clock 4 MIN
  • calendar Dec 2024

Educational programme supported by an Independent Educational Grant from Eisai Europe Limited (“Eisai”). Eisai has had no input on the educational content of, or speakers involved in this programme. 
micro-learning Micro learning
Oncology 
Metastatic pancreatic ductal adenocarcinoma (PDAC): from diagnosis to treatment

Risk factors, diagnostic tools and treatment options for different patient groups

Experts
Prof. Efrat Dotan, Prof. Shubham Pant
Endorsed by
Digestive Cancers Europe
  • download Downloadable
    Resources
  • clock 4 MIN
  • calendar Dec 2024

Educational programme supported by an Independent Educational Grant from Ipsen USA.
conference-update Conference update
Oncology 
Rezatapopt in TP53 Y220C mutated metastatic breast cancer: PYNNACLE phase 1/2 update

Exploring emerging treatment strategies presented at SABCS 2024

Experts
Prof. Frédérique Penault-Llorca, Dr Ecaterina E Dumbrava
  • download Downloadable
    Resources
  • clock 5 MIN
  • calendar Dec 2024

This programme has been sponsored by PMV Pharma.